Mutational analysis of HRAS and KRAS genes in oral carcinoma cell lines
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
RAS overexpression and its active mutations are involved in malignant tumorigenesis. However, the mutation rates in oral carcinoma cells differ between populations. In the present study, genomic DNA of oral carcinoma cells (HOC313, TSU, HSC2, HSC3, KOSC2, KOSC3, SCCKN, OSC19, Ca9.22, and Ho1u1 cells) or normal gingival fibroblasts (GF12 cells) derived from a Japanese population were amplified by polymerase chain reaction using primer sets, spanning HRAS and KRAS exons. Nucleotide substitutions were analyzed by single strand conformation polymorphism. In contrast to no substitutions in KRAS, nine different substitutions were detected in HRAS. Of the nine, six substitutions were located at intron 1 (HSC2 and HSC3 cells) or intron 2 (HSC3, SCCKN and Ca9.22 cells), and one each of exon 1 (all cells), exon 2 (HOC313, TSU, HSC2 and HSC3 cells) and the 5′ upstream region (all cells). Substitutions at exons 1 and 2 did not affect the amino acid sequence; the exon 1 substitution was positioned at the 5′ untranslated region, which may be a single nucleotide polymorphism (SNP) sequence because all the cells were isolated from a Japanese population, and the mutations at exon 2 was a silent mutation. A substitution at the 5′ upstream region was an SNP. These data demonstrate that SNPs and point mutations observed in HRAS do not change the amino acid sequence, and suggest that the mutations affecting the amino acid sequence may be a rare event in oral carcinomas of the Japanese population.
- Johnson N. Tobacco use and oral cancer: a global perspective. J Dent Educ. 2001;65:328–39.
- Choi S, Myers JN. Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. J Dent Res. 2008;87:14–32. CrossRef
- Vora HH, Shah NG, Patel DD, Trivedi TI, Chikhlikar PR. Prognostic significance of biomarkers in squamous cell carcinoma of the tongue: multivariate analysis. J Surg Oncol. 2003;82:34–50. CrossRef
- Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003;3:7–13. CrossRef
- Maeda G, Chiba T, Aoba T, Imai K. Epigenetic inactivation of E-cadherin by promoter hypermethylation in oral carcinoma cells. Odontology. 2007;95:24–9. CrossRef
- Miyazawa J, Mitoro A, Kawashiri S, Chada KK, Imai K. Expression of mesenchyme-specific gene HMGA2 in squamous cell carcinomas of the oral cavity. Cancer Res. 2004;64:2024–9. CrossRef
- Saranath D, Chang SE, Bhoite LT, Panchai RG, Kerr IB, Mehta AR, Johnson NW, Deo MG. High frequency mutation in codons 12 and 61 of H-ras oncogene in chewing tobacco-related human oral carcinoma in India. Br J Cancer. 1991;63:573–8. CrossRef
- Hardisson D. Molecular pathogenesis of head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2003;260:502–8. CrossRef
- Lu SL, Herrington H, Reh D, Weber S, Bornstein S, Wang D, Li AG, Tang CF, Siddiqui Y, Nord J, Andersen P, Corless CL, Wang XJ. Loss of transforming growth factor-β type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes Dev. 2006;20:1331–42. CrossRef
- Kuo MYP, Jeng JH, Chiang CP, Hahn LJ. Mutation of Ki-ras oncogene codon 12 in betel quid chewing-related human oral squamous cell carcinoma in Taiwan. J Oral Pathol Med. 1994;23:70–4. CrossRef
- Yarbrough WG, Shores C, Witsell DL, Weissler MC, Fidler ME, Gilmer TM. Ras mutations and expression in head and neck squamous cell carcinomas. Laryngoscope. 1994;104:1337–47. CrossRef
- Huang KH, Huang SF, Chen IH, Liao CT, Wang HM, Hsieh LL. Methylation of RASFF1A, RASFF2A, and HIN-1 is associated with poor outcome after radiotherapy, but not surgery, in oral squamous cell carcinoma. Clin Cancer Res. 2009;15:4174–80. CrossRef
- Sakata K. Alterations of tumor suppressor genes and the H-ras oncogene in oral squamous cell carcinoma. J Oral Pathol Med. 1996;25:302–7. CrossRef
- Chang SE, Bhatia P, Johnson NW, Morgan PR, McCormick F, Young B, Hiorns L. Ras mutations in United Kingdom examples of oral malignancies are infrequent. Int J Cancer. 1991;48:409–12. CrossRef
- Kok SH, Lee JJ, Hsu HC, Chiang CP, Kuo YS, Kuo MYP. Mutations of the adenomatous polyposis coli gene in areca quid and tobacco-associated oral squamous cell carcinomas in Taiwan. J Oral Pathol Med. 2002;31:395–401. CrossRef
- Quintanilla M, Brown K, Ramsden M, Balmain A. Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature. 1986;332:78–80. CrossRef
- Das N, Majumder J, DasGupta UB. Ras gene mutations in oral cancer in eastern India. Oral Oncol. 2000;36:76–80. CrossRef
- Kiaris H, Spandidos DA, Jones AS, Vaughan ED, Field JK. Mutations, expression and genomic instability of the H-ras proto-oncogene in squamous cell carcinomas of the head and neck. Br J Cancer. 1995;72:123–8. CrossRef
- Azuma M, Furumoto N, Kawamata H, Yoshida H, Yanagawa T, Yura Y, Hayashi Y, Takegawa Y, Sato M. The relation of ras oncogene product p21 expression to clinicopathological status criteria and clinical outcome in squamous cell head and neck cancer. Cancer J. 1987;1:375–80.
- Tsuji T, Sasaki K, Hiraoka F, Shinozaki F. The immunohistochemical detection of ras p21 and its correlation with differentiation in oral cancers. J Tumour Marker Oncol. 1998;4:415–9.
- Bernhard EJ, Stanbridge EJ, Gupta S, Gupta AK, Soto D, Bakanauskas VJ, Cerniglia GJ, Muschel RJ, McKenna WG. Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines. Cancer Res. 2000;60:6577–600.
- Ling CC, Endlich B. Radioresistance induced by oncogenic transformation. Radiat Res. 1989;120:267–79. CrossRef
- Miller AC, Kario K, Myers CE, Clark EP, Samid D. Increased radioresistance of EJras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation. Int J Cancer. 1993;53:302–7. CrossRef
- Suzuki R, Kohno H, Suzui M, Yoshimi N, Tsuda H, Wakabayashi K, Tanaka T. An animal model for the rapid induction of tongue neoplasms in human c-Ha-ras proto-oncogene transgenic rats by 4-nitroquinoline 1-oxide: its potential use for preclinical chemoprevention studies. Carcinogenesis. 2006;27:619–30. CrossRef
- Raimondi AR, Molinolo A, Gutkind JS. Rapamycin prevents early onset of tumorigenesis in an oral-specific K-ras and p53 two-hit carcinoma model. Cancer Res. 2009;69:4159–66. CrossRef
- Sasaki E, Tsuchida N. Most human squamous cell carcinomas in the oral cavity contain mutated p53 tumor-suppressor genes. Oncogene. 1992;7:927–33.
- Inagaki T, Matsuwari S, Takahashi R, Shimada K, Fujie K, Maeda S. Establishment of human oral-cancer cell lines (KOSC-2 and KOSC-3) carrying p53 and C-myc abnormalities by geneticin treatment. Int J Cancer. 1994;56:301–8. CrossRef
- Poeta ML, Manola JM, Goldwasser MA, Forastiere A, Benoit N, Califano JA, Ridge JA, Goodwin J, Kenady D, Saunders J, Westra W, Sidransky D, Koch WM. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med. 2007;357:2552–61. CrossRef
- Rubin Grandis J, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, Drenning SD, Tweardy DJ. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 1998;90:824–32. CrossRef
- Lo KW, Kwong J, Hui AB, Chan SY, To KF, Chan AS, Chow LS, Teo PM, Johnson PJ, Huang DP. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res. 2001;61:3877–81.
- Weber A, Langhanki L, Sommerer F, Markwarth A, Wittekind C, Tannapfel A. Mutations of the BRAF gene in squamous cell carcinoma of the head and neck. Oncogene. 2003;22:4757–9. CrossRef
- Mutational analysis of HRAS and KRAS genes in oral carcinoma cell lines
Volume 100, Issue 2 , pp 149-155
- Cover Date
- Print ISSN
- Online ISSN
- Springer Japan
- Additional Links
- Oral carcinoma
- Author Affiliations
- 1. Department of Biochemistry, The Nippon Dental University, School of Life Dentistry at Tokyo, 1-9-20 Fujimi, Chiyoda-ku, Tokyo, 102-8159, Japan